Atopic Dermatitis – Drug Pipeline Landscape, 2022

Global Analysis Services

Global Insight Services recently released Atopic Dermatitis – Drug Pipeline Landscape 2022 report. The pipeline landscape report provides analysis of pipeline products based on multiple development stages ranging from discovery to pre-registration .

Request a sample report:

Atopic dermatitis (eczema) is a condition that causes dry, itchy, and inflamed skin. It is characterized by inflamed skin that may split open and release clear fluid when scratched. Eczema damages the skin barrier function which makes the skin more sensitive and more prone to infection and dryness.

Atopic dermatitis is caused by a combination of immune system activation, genetics, environmental triggers, and stress. Weak skin barrier function can also trigger an immune system response that causes inflamed skin and other symptoms.

Symptoms of atopic dermatitis (eczema) include dry, cracked skin, itching, rashes, bumps, on brown or black skin, oozing and crusting, thickened skin, darkening of the skin around the eyes, sensitive skin from scratching.

Report Highlights

Global Insight Service’s 2022 report, Atopic Dermatitis – Drug Pipeline Landscape, provides an overview of drugs in the pipeline for atopic dermatitis. This report covers detailed information on atopic dermatitis drugs in development, evaluation by target, mechanism of action, route of administration and molecule type. Product portfolio by company, development stage and key regulatory designations, agreements and milestones have been presented to provide information and thus help industry players in their decision-making. The Atopic Dermatitis Pipeline report helps in understanding the drugs that are in the development stage of the drug development process globally.


The pipeline landscape report provides an analysis of pipeline products based on multiple development stages ranging from discovery to pre-registration. The report provides a review of the companies’ in-process therapeutics based on information from company and industry specific sources. The pipeline report covers the evaluation of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA), and molecule type. Full pipeline product profiles with details such as company overview, stage of development; Molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key agreements, clinical trials, and major upcoming milestones are included.

Find out before you buy:

Report segmentation
– Assessment by stage of development
– Evaluation by companies
– Evaluation by target
– Assessment by mechanism of action
– Evaluation by type of molecule
– Evaluation by route of administration

Some of the key players involved in the development of atopic dermatitis therapeutics are:

• 3SBio Inc.
• AbbVie
• Aclaris Therapeutics, Inc.
• Akaal Pharma Pty Ltd
• Akesobio Australia Pty Ltd
• Allakos, Inc.
• Amgen
• Amtixbio Co Ltd
• Amytrx Therapeutics, Inc.
• AOBiome LLC
• Arcutis Biotherapeutics, Inc.
• Arena Pharmaceuticals
• Arjil Pharmaceuticals LLC
• Asana BioSciences
• ASLAN Pharmaceuticals
• Astra Zeneca
• Atrapos Therapeutics LLC
• Avixgen Inc.
• Azitra Inc.
• BenevolentAI Bio
• BioMarck Pharmaceuticals Ltd.


The research process includes extensive secondary research of public domain and other authentic sources to add or update pipeline product information. Secondary research sources include, but are not limited to, company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences and clinical trial registries.

Contact us:

Global Insight Services LLC
16192 Coast Road, Lewes DE 19958
Email: [email protected]
Phone: +1-833-761-1700

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research company headquartered in Delaware, USA. We are committed to providing our clients with the highest quality data, analysis and tools to meet all of their market research needs. With GIS, you can be assured of quality deliverables, a robust and transparent research methodology, and superior service.

This press release was published on openPR.

Comments are closed.